ABSTRACT
Background: Hematologic toxicity is a severe complication of chemotherapy. The objective of our study is to evaluate the impact of early lymphopenia on the risk of occurrence of febrile neutropenia and hematological toxicity after aggressive chemotherapy for Hodgkin lymphoma or high grade non-Hodgkin lymphoma
Methods: This prospective study involved 42 patients who received 193 cycles of chemotherapy in 2009. We assessed the impact of lymphopenia on day 1 and 8 on the risk of occurrence of febrile neutropenia. We also investigated the relation between the occurrence of hematologic toxicity after the first cycle and the subsequent cycles
Results: Febrile neutropenia was observed in 25% of cycles. Grade 3/4 hematologic toxicity occurred in 63% of cycles. Growth factors were used in 79% of cycles. Lymphopenia = 700/mm3 on day1 and 8 was noted in 21% and 65% of cycles. If the lymphocyte count was =700/mm3 on day1, the risk of febrile neutropenia was significantly higher [p=0.042] and the mean duration of antibiotic therapy longer [p = 0.013]. Lymphopenia =700/mm3 on day 8 was associated with a greater risk of febrile neutropenia in univariate analysis [OR=2.4; p=0.02]. Moreover analyzes showed that this factor was significantly associated with increase in hematologic toxicity [p=0.02], duration of neutropenia [p=0.001] and duration of antibiotics [p=0.05]. Hematologic toxicity during the first cycle was predictive of its occurrence in subsequent cycles of chemotherapy [p=0.028]
Conclusion: Our results confirmed the impact of early lymphopenia on the occurrence of febrile neutropenia and hematologic toxicity after aggressive chemotherapy for Hodgkin lymphoma or high grade non Hodgkin lymphoma
ABSTRACT
Sweet's syndrome is an acute febrile neutrophilic dermatosis. This condition is characterized by the sudden onset of fever and tender, erythematous, well-demarcated papules which show dense neutrophilic infiltrates on histological examination. Sweet's syndrome is often associated with hematologic disease including myeloid leukemia. Aim: Report of news cases of Sweet's syndrome. We report two cases of Sweet's syndrome occurring respectively after the use of Granulocyte-Colony Stimulating Factor [G-CSF], and the All-Trans-Retinoic-Acid [ATRA] in two females aged respectively 46 and 35 years. The outcome was favourable in the two cases